[go: up one dir, main page]

CO5580743A2 - Piperidinas y piperazinas 3,4-disustituidas, 3,5- disustituidas y 3,4,5-sustituidas - Google Patents

Piperidinas y piperazinas 3,4-disustituidas, 3,5- disustituidas y 3,4,5-sustituidas

Info

Publication number
CO5580743A2
CO5580743A2 CO04048699A CO04048699A CO5580743A2 CO 5580743 A2 CO5580743 A2 CO 5580743A2 CO 04048699 A CO04048699 A CO 04048699A CO 04048699 A CO04048699 A CO 04048699A CO 5580743 A2 CO5580743 A2 CO 5580743A2
Authority
CO
Colombia
Prior art keywords
alkyl
aryl
alkoxy
heteroaryl
optionally substituted
Prior art date
Application number
CO04048699A
Other languages
English (en)
Inventor
John Varghese
Joseph B Moon
R Pulley Shon
Daniel H Rich
David L Brown
Barbara Jagodzinska
Jon Jacobs
Original Assignee
Elan Pharm Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Upjohn Co filed Critical Elan Pharm Inc
Publication of CO5580743A2 publication Critical patent/CO5580743A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de la fórmula I: o una sal farmacéuticamente aceptable o uno de sus ésteres, en donde Z es CH o N;en donde R1 y R3 son, de modo independiente:(I) alquilo C1-C10, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados, de modo independiente, del grupo integrado por alquilo C1-C3, -F, -Cl, -Br, -I, -OH, -SH, -C=N, -CF3, alcoxi C1-C3, -O-fenilo, -NR1-aR1-b, en donde R1-a y R1-b son, de modo independiente -H o alquilo C1-C6, -OC=O NR1-aR1-b, -S(=O)0-2 R1-a, -NR1-aC=O NR1-aR1-b, -C=O NR1-aR1-b, y -S(=O)2 NR1-aR1-b, -(CH2)0-3-(C3-C8) cicloalquilo, en donde el cicloalquilo puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados del grupo integrado por alquilo C1-C3, -F, -Cl, -Br, -I, -OH, -SH, -C=N, -CF3, alcoxi C1-C6, -O- fenilo, -CO-OH, -CO-O- (alquilo C1-C4), -NR1-aR1-b; alcoxi C1-C3-(R1-arilo), alcoxi C1-C3 - (R1-heteroarilo),(II) - (CH2)n1- (R1-arilo), en donde n1 es cero o uno y, en donde R1-arilo es fenilo, 1-naftilo, 2 -naftilo e indanilo, indenilo, dihidronaftilo, tetralinilo opcionalmente sustituido con uno, dos, tres o cuatro de los siguientes sustituyentes seleccionados, de modo independiente, en el anillo arilo:(1) alquilo C1-C6 opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados, de modo independiente, del grupo integrado por alquilo C1-C3, -F, -Cl, -Br, -I, -OH, -SH, -S(alquilo C1-6), -S(aril-alquilo C1-6), S(heteroaril-alquilo C1-6), -S=O(alquilo C1-6), -S=O(arilalquilo C1-6), -S=O(heteroaril-alquilo C1-6), -SO2(alquilo C1-6), -SO2(aril-alquilo C1-6), -SO2 (heteroaril-alquilo C1-6), -NR1-aR1-b, -C=N, -CF3, alcoxi C1-C3, alcoxi C1-C3-(R1-arilo), alcoxi C1-C3 - (R1-heteroarilo), (2) alquenilo C2-C6 con uno o dos enlaces dobles, opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados, de modo independiente, del grupo integrado por -F, -Cl, -Br, -I, -OH, -SH, -S(alquilo C1-6), -S(aril-alquilo C1-6), -S(heteroaril-alquilo C1-6), -S=O (alquilo C1-6), S=O(aril-alquilo C1-6), -S=O(heteroaril-alquilo C1-6), SO2(alquilo C1-6), -SO2(aril-alquilo C1-6), -SO2(heteroaril-alquilo C1-6), -C=N, -CF3, alcoxi C1-C3, -NR1-aR1-b, alcoxi C1-C3-(R1-arilo), alcoxi C1-C3 - (R1-heteroarilo), ...
CO04048699A 2001-11-19 2004-05-26 Piperidinas y piperazinas 3,4-disustituidas, 3,5- disustituidas y 3,4,5-sustituidas CO5580743A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33270801P 2001-11-19 2001-11-19
US38316702P 2002-05-24 2002-05-24

Publications (1)

Publication Number Publication Date
CO5580743A2 true CO5580743A2 (es) 2005-11-30

Family

ID=26988352

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04048699A CO5580743A2 (es) 2001-11-19 2004-05-26 Piperidinas y piperazinas 3,4-disustituidas, 3,5- disustituidas y 3,4,5-sustituidas

Country Status (21)

Country Link
US (1) US7338965B2 (es)
EP (1) EP1448200A2 (es)
JP (1) JP2005514362A (es)
KR (1) KR20050044533A (es)
AP (1) AP2004003052A0 (es)
AU (1) AU2002360403A1 (es)
BR (1) BR0214295A (es)
CA (1) CA2467749A1 (es)
CO (1) CO5580743A2 (es)
EA (1) EA200400699A1 (es)
GE (1) GEP20074045B (es)
HR (1) HRP20040550A2 (es)
IL (1) IL162079A0 (es)
IS (1) IS7271A (es)
MX (1) MXPA04004772A (es)
NO (1) NO20042580L (es)
NZ (1) NZ533158A (es)
OA (1) OA12812A (es)
RS (1) RS54204A (es)
TN (1) TNSN04088A1 (es)
WO (1) WO2003043987A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2006235344B2 (en) 2005-04-08 2012-07-26 Comentis, Inc. Compounds which inhibit beta-secretase activity and methods of use thereof
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
EP3231442B1 (en) 2006-06-23 2019-12-25 ADC Therapeutics SA Polynucleotides and polypeptide sequences involved in cancer
KR100679869B1 (ko) * 2006-10-27 2007-02-07 한국기계연구원 Ｄｐｆ시스템용 플라즈마 반응기와 이를 이용한 입자상물질의 저감 장치
JP2010504330A (ja) 2006-09-21 2010-02-12 メルク エンド カムパニー インコーポレーテッド アルツハイマー病治療のためのピペリジンおよびピロリジンベータ−セクレターゼ阻害剤
KR100838645B1 (ko) * 2006-09-28 2008-06-16 한국화학연구원 베타-세크리테아제 활성을 억제하는 피페리딘 화합물
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
KR100894713B1 (ko) * 2007-10-08 2009-04-24 한국화학연구원 베타-세크리테아제의 활성을 저해하는 아릴피페라진이 치환된 피페리딘 유도체 또는 이의 약제학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 신경퇴행성 질환의 예방 또는 치료용 조성물
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
CA2772488C (en) 2009-09-11 2018-04-17 Probiodrug Ag Heterocyclic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
PL3173427T3 (pl) 2011-03-31 2019-11-29 Adc Therapeutics Sa Przeciwciała przeciwko antygenowi związanemu z nerkami 1 i ich fragmenty wiążące antygen
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4248876A (en) 1977-01-08 1981-02-03 John Wyeth & Brother Ltd. Piperidine derivatives
US5142056A (en) 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3640475A1 (de) * 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
IE63906B1 (en) * 1987-11-13 1995-06-14 Novo Nordisk As Azabicyclic compounds and their preparation and use
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
US5708004A (en) 1990-11-19 1998-01-13 Monsanto Company Retroviral protease inhibitors
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US5475138A (en) 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
IL123293A (en) * 1995-09-07 2003-06-24 Hoffmann La Roche Piperidine derivatives, their preparation and pharmaceutical compositions containing them
JP2001510474A (ja) 1997-02-04 2001-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア カテプシンｄのナノモルの非ペプチド阻害剤
AU9740998A (en) * 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
EP1034174B1 (en) * 1997-11-05 2003-08-13 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
HUP0101320A3 (en) * 1998-01-21 2002-11-28 Kyowa Hakko Kogyo Kk Benzo- and pyridobenzoxepine and -benzazepine derivatives and use thereof
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
BR9912013A (pt) * 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
EP1119553A1 (en) * 1998-10-07 2001-08-01 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
GB9904786D0 (en) 1999-03-02 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2002066469A2 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
AU2002306848A1 (en) 2001-03-23 2002-10-08 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
AU2002256418A1 (en) * 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace

Also Published As

Publication number Publication date
KR20050044533A (ko) 2005-05-12
BR0214295A (pt) 2004-11-09
AU2002360403A1 (en) 2003-06-10
JP2005514362A (ja) 2005-05-19
OA12812A (en) 2006-07-10
AP2004003052A0 (en) 2004-06-30
US7338965B2 (en) 2008-03-04
CA2467749A1 (en) 2003-05-30
NZ533158A (en) 2006-09-29
MXPA04004772A (es) 2005-06-06
WO2003043987A3 (en) 2003-07-10
IL162079A0 (en) 2005-11-20
NO20042580L (no) 2004-08-09
EP1448200A2 (en) 2004-08-25
HRP20040550A2 (en) 2006-11-30
US20040034031A1 (en) 2004-02-19
GEP20074045B (en) 2007-02-26
WO2003043987A2 (en) 2003-05-30
TNSN04088A1 (en) 2006-06-01
IS7271A (is) 2004-05-19
EA200400699A1 (ru) 2004-12-30
RS54204A (sr) 2006-12-15

Similar Documents

Publication Publication Date Title
CO5580743A2 (es) Piperidinas y piperazinas 3,4-disustituidas, 3,5- disustituidas y 3,4,5-sustituidas
CO5550472A2 (es) Piperazinas heterociclicas sustituidas para el tratamiento de la esquizofrenia
PE20221277A1 (es) Inhibidores de ras
CO5640093A2 (es) Derivados n-n` sustituidos de 1.3 diamino-2-hidroxipropano
CO5640095A2 (es) Hidroxietilaminas sustituidas
KR100481124B1 (ko) 폴리히드록시알카노에이트의 제조에 이용되는 미생물
ES2175919T3 (es) Derivados del camptothecin con actividad antitumoral.
KR870007116A (ko) 인돌 유도체의 제조방법
HUP0300138A2 (en) Cyclic amine derivatives as ccr5 antagonists, their production and use and pharmaceutical compositions containing them
DK0610134T3 (da) Indolderivater som 5-HT,1-lignende agonister
CO5540299A2 (es) Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas
ATE202702T1 (de) Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung
ECSP077215A (es) Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica
HUP9904167A2 (hu) 1,4-Diszubsztituált piperazin- és piperidinszármazékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
JP2005504729A5 (es)
WO2004000762A3 (en) Propionic acid derivatives and their use as hppars activators
CO4930274A1 (es) Tiazol bencenosulfonamidas como agonistas b3 para el trata- miento de la diabetes y la obesidad
CO5690582A2 (es) Derivados de n-tiazol-2-il-benzamida
CY1108148T1 (el) Αβερμεκτινης- και μονοσακχαριτη αβερμεκτινης παραγωγα υποκατεστημενα στην 4''- ή 4'- θεση που εχουν ζιζανιοκτονες ιδιοτητες
KR860001074A (ko) 생물학적으로 활성인 질소함유 헤테로시클릭 화합물의 제조방법
HUP0400772A2 (hu) Eljárás piperazinszármazékok mezilátjainak előállítására és ezen vegyületek
PT90912A (pt) Processo para a preparacao de derivados de tiofenol
AR039122A1 (es) Derivados de ftalimido como inhibidores de monoamino oxidasa b
ATE182589T1 (de) Verfahren zur herstellung von benzyliden- derivaten
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.

Legal Events

Date Code Title Description
FC Application refused